造血干细胞移植相关的急性肾损伤与慢性肾脏病
造血干细胞移植可导致血管性、肾小球性和小管间质性肾损伤,急性肾损伤发生率为10%-73%,约5%需肾脏替代治疗,高达60%受者发生慢性肾脏病。急性肾损伤普遍与更高的全因和非复发死亡率相关,需急性透析者死亡率超过80%。预防、早期识别和及时治疗是改善肾脏和患者结局的关键。
要点
- 造血干细胞移植后急性肾损伤常见,发生率为10%-73%。
- 急性肾损伤与更高的全因和非复发死亡率普遍相关。
- 需急性透析者死亡率超过80%,应重视预防和早期识别。
核心结论
- 造血干细胞移植相关肾损伤包括血管性、肾小球性和小管间质性异常,急性肾损伤常见且与高死亡率相关。
研究设计与样本
- 本文为综述,总结造血干细胞移植相关急性肾损伤和慢性肾脏病的发生、病因、危险因素及结局。
主要发现
- 急性肾损伤发生于10%-73%的移植患者,约5%需肾脏替代治疗,高达60%受者发生慢性肾脏病。
- 急性肾损伤病因常为多因素,包括脓毒症、肾毒性药物、骨髓输注综合征、肝窦阻塞综合征、血栓性微血管病、感染和移植物抗宿主病。
- 急性肾损伤普遍与更高的全因和非复发死亡率相关,需急性透析者死亡率超过80%。
临床怎么用
- 应重视造血干细胞移植后肾损伤的预防、早期识别和及时治疗,以改善肾脏和患者结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hematopoietic stem cell transplantation is a life-saving therapy for many patients with cancer, as well as patients with some nonmalignant hematologic disorders, such as aplastic anemia, sickle cell disease, and certain congenital immune deficiencies. Kidney injury directly associated with stem cell transplantation includes a wide range of structural and functional abnormalities, which may be vascular (hypertension, thrombotic microangiopathy), glomerular (albuminuria, nephrotic glomerulopathies), and/or tubulointerstitial. AKI occurs commonly after stem cell transplant, affecting 10%-73% of patients. The cause is often multifactorial and can include sepsis, nephrotoxic medications, marrow infusion syndrome, hepatic sinusoidal obstruction syndrome, thrombotic microangiopathy, infections, and graft versus host disease. The risk of post-transplant kidney injury varies depending on patient characteristics, type of transplant (allogeneic versus autologous), and choice of chemotherapeutic conditioning regimen (myeloablative versus nonmyeloablative). Importantly, AKI is associated with substantial morbidity, including the need for KRT in approximately 5% of patients and the development of CKD in up to 60% of transplant recipients. AKI has been associated universally with higher all-cause and nonrelapse mortality regardless of transplant type, and studies have consistently shown extremely high (>80%) mortality rates in those patients requiring acute dialysis. Accordingly, prevention, early recognition, and prompt treatment of kidney injury are essential to improving kidney and patient outcomes after hematopoietic stem cell transplantation, and for realizing the full potential of this therapy.
引用
- Renaghan AD, Jaimes EA, Malyszko J, et al. Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation. Clin J Am Soc Nephrol. 2019. PMID: 31836598. doi:10.2215/CJN.08580719
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。